2026³â 02¿ù 26ÀÏ ¸ñ¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Berry Consultants Releases FACTS 8 Clinical Trial Simulator

FACTS 8 introduces support for Ordinal endpoints and a new ¡°Quick Start¡± feature.
´º½ºÀÏÀÚ: 2025-11-26

AUSTIN, TEXAS -- Berry Consultants, LLC announced the release of FACTS 8, the latest version of its industry-leading Fixed and Adaptive Clinical Trial Simulator (FACTS). FACTS 8 is now available to both existing users and new clients worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023501254/en/

FACTS is the most powerful, flexible, and efficient platform for designing and simulating clinical trials across the full spectrum of drug development — from early Phase I studies to complex, multi-arm platform trials. The new release introduces two major advancements:

· Full simulation of ordinal endpoints in Phase II and Phase III trial designs, enabling powerful designs with frequentist and Bayesian methods of analysis.
· A Quick Start feature that streamlines setup for fixed and group sequential trials while maintaining the full simulation power FACTS provides for more customized adaptive designs.

“Ordinal endpoints are ubiquitous in clinical trials and the ability to optimize the analyses and design for trials utilizing them is becoming increasingly important,” said Scott Berry, PhD, President and Senior Statistical Scientist at Berry Consultants. “With FACTS 8, we’re giving researchers a unified platform to evaluate and compare analytical methods for these endpoints — from dichotomization, non-parametric Wilcoxon tests, proportional odds testing, Bayesian Dirichlet models, to utility weighting. This capability allows teams to directly compare performance, make better design choices, and ultimately improve clinical research.”

The Ordinal Endpoint Module in FACTS 8 supports simulation of one-, two-, or multi-arm trials and includes the full range of adaptive design features — early stopping, arm dropping, and response-adaptive randomization.

“This release not only extends the power and range of FACTS, but also makes simulation of conventional trials faster and easier,” added Tom Parke, Director of Software Solutions at Berry Consultants. “The new Quick Start feature allows users to set up and run standard designs in minutes, while retaining the same detailed simulation engine that powers our most advanced adaptive trials.”

With these enhancements, FACTS continues to reflect Berry Consultants’ philosophy that clinical trial simulation should be intuitive, transparent, and comprehensive. FACTS enables users to specify and compare designs across the entire range of trial types — from simple fixed designs to the most innovative adaptive platforms — supporting smarter and more 



 Àüü´º½º¸ñ·ÏÀ¸·Î

Concept Medical Begins STARS DAPT Trial With First Patient for Abluminus NP Polymer-Free DES
Research From Lenovo Reveals AI Is Paying Off, Yet Most CIOs Aren¡¯t Ready for What Comes Next
Revolutionizing 5G Network Slice Testing: Industry-First Performance Methodology by Ookla and Ericsson
Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis
Copeland Advances AI and Digital Strategy with Acquisition of Bueno Analytics
Vestas Secures 390 MW Offshore Order in South Korea
Syngenta to Tackle Global Farm Challenges at WEF, Driving AI Innovation and Open Tech Access for Farmers

 

Philip Morris International Opens Dialogue on the Future of Human Cogn...
Crown Bioscience San Diego Lab Earns CAP Accreditation, Expands Clinic...
Axelspace Signs MoU with Ethiopian Company to Address Social Challenge...
Parse Biosciences and Graph Therapeutics Partner to Build Large Functi...
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
Innovative Research Unveils Potential of Pharmaceutically Processed Mi...
Sisvel Launches Wi-Fi Multimode Patent Pool

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..